Johnson & Johnson - Dry Powder? Header Image

Johnson & Johnson - Dry Powder?

Article headline image. Paul Truesdell on

Posted in  Johnson & Johnson, Reuters, News Bias, Litigation, Baby Powder, Shorting Stock, Stock Manipulation

For more than 40 years there have been suspicions in the medical industry that the use of talcum powder is related to the development of cancer in the reproductive system. Though the development of ovarian cancer is likely dependent upon a number of factors, there is some evidence that talc particles may travel through the vagina and fallopian tubes and to the ovaries, increasing the risk for development of ovarian cancer.

The first study linking the use of talcum powder to ovarian cancer was conducted in 1971 when researchers found that 75% of the ovarian cancer tumors contained talc particles. A decade later, a Harvard University researcher found a 30% increase in ovarian cancer in women who used talcum powder products frequently. A 1997 internal memo shows that Johnson & Johnson, manufacturer of Johnson & Johnson’s Baby Powder and Shower-to-Shower body powder, knew of the potential risk but believed the risk was too low to justify warnings or discontinue marketing their products.

Bad actors and possible bad actors.

Over $5 billion has been awarded to ovarian cancer lawsuit plaintiffs but more than 9,000 cases have yet to be settled including:

  • 6,900 federal lawsuits in U.S. District Court in New Jersey
  • 500 state lawsuits in New Jersey State Court in Atlantic County
  • 800 state lawsuits in Los Angeles Superior Court in California
  • 1,700 state lawsuits in St. Louis Circuit Court in Missouri

Think about it.